Scientific article
OA Policy
French

Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ?

Other titleTreatment of SARS-CoV-2 in paediatrics : what is the evidence to date?
Published inRevue médicale suisse, vol. 17, no. 726, p. 344-348
Publication date2021-02-17
Abstract

Although SARS-CoV-2 infects individuals of all ages, children show less severe symptoms. Nevertheless, the very rare COVID-19 severe cases in paediatrics require our full attention. Much research has been conducted and is still ongoing on effective treatments. On the antiviral front, no molecule has been proven effective yet and the results of several studies on the benefit of monoclonal antibodies and convalescent plasma are pending. On the side of immunomodulators, the benefit of steroids has been demonstrated for patients severely ill. Other molecules are being investigated. However, all these studies focused on adults and paediatric data are warranted.

Keywords
  • Adult
  • COVID-19 / therapy
  • Child
  • Coronavirus Infections
  • Humans
  • Immunization, Passive
  • Pediatrics
  • SARS-CoV-2
Citation (ISO format)
FOUGERE, Yves et al. Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? In: Revue médicale suisse, 2021, vol. 17, n° 726, p. 344–348. doi: 10.53738/REVMED.2021.17.726.0344
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN1660-9379
202views
176downloads

Technical informations

Creation01/03/2022 15:43:00
First validation01/03/2022 15:43:00
Update10/02/2026 08:25:03
Status update10/02/2026 08:25:03
Last indexation10/02/2026 08:25:14
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack